Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ: SPRC )

0.2453 -0.0437 (-15.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SciSparc Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
From SciSparc Ltd
Via GlobeNewswire
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
From SciSparc Ltd
Via GlobeNewswire
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
From SciSparc Ltd
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From SciSparc Ltd
Via GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
From SciSparc Ltd
Via GlobeNewswire
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
From SciSparc Ltd
Via GlobeNewswire
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
From SciSparc Ltd
Via GlobeNewswire
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
From SciSparc Ltd
Via GlobeNewswire
SciSparc Updates Regarding the Status of the AutoMax Merger
From SciSparc Ltd
Via GlobeNewswire
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
From SciSparc Ltd
Via GlobeNewswire
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
From SciSparc Ltd
Via GlobeNewswire
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
From SciSparc Ltd
Via GlobeNewswire
SciSparc Secures Strategic Advantage with Grant of European Patent
From SciSparc Ltd
Via GlobeNewswire
SciSparc to Acquire AutoMax
From SciSparc Ltd
Via GlobeNewswire
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
From SciSparc Ltd
Via GlobeNewswire
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
From SciSparc Ltd
Via GlobeNewswire
SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure
From SciSparc Ltd
Via GlobeNewswire
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.